contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

“Treatment-naive HR (IPSS-R >3; n=21) and HMA r/r (n=32) MDS patients were recruited in the Phase 1/2 BEXMAB study.” Sometimes HR MDS n=20 and sometimes 21. Fluctuations of one patient can be explained by this. The difference between abstract/poster 17% vs 57% is big. This is a bigger difference for which a layman cannot find an explanation. Since the difference is big, an explanation surely exists. It would be interesting to hear, but this does not yet arouse distrust in me.

Faron should clarify in a statement whether these 4 patients were Baseline TD or not. Also, what causes the 17% vs 57% difference between the abstract (which is peer-reviewed information) and the poster and press release. From the abstract, the patient count can be calculated as 1/6; in the poster, it is 4/7, so the difference is not entirely due to a different sample. It has also not been stated that the data cut for the abstract and the poster was at a different time. The assumption is that the abstract and poster describe the data at the same point in time, unless otherwise specified. In my opinion, the poster clearly presents patients who were TD at some point during treatment, after screening, and achieved TI. And this is perfectly fine; researchers can present what they want. But the statement appears to be incorrectly worded, or at least it is easily misleading.

What, what, Clark K. just said that the treatment CAUSES the need for transfusions (TD). In his message: “Point B mainly communicates that as a combined effect of the disease and the treatment, a temporary need for transfusions developed, which then resolved.” My advice: focus on the ball, i.e., business development activities, that’s where the next news will come from. Soon.

Siltanen had a somewhat different opinion on this in his comment:  Transfusion independence is a clinically significant factor, as it improves patients’ quality of life and reduces the burden on healthcare. Azacitidine monotherapy is known to lead to transfusion independence in some patients. The role of Bexmarilimab regarding TI is difficult to assess at this stage.  The source referenced in the comment states:  Transfusion independence (TI) for red blood cells (RBC) was achieved in 45.9% of transfusion-dependent patients and in 30% for platelets.  In that study, patients received AZA alone.                   PubMed              Alternative 5-Azacitidine 5-Day 100 mg/m2 Dosage Shows Non-Inferiority to...    The authors have confirmed clinical trial registration is not needed for this submission.

So wait a minute, wait a minute. Is Faron so incompetent that they publish such a slide as an achievement, even though in the case of a big scam, they should have understood to hide it? How is it that I trust Faron’s experts and SAB more than a forum bear who has spent all their energy in recent years finding that typo/word salad/hidden grain of information, so that this BIG scam is finally revealed. A bear market always seems to be fuel for these people. In the summer, when things were really green, they already had to start looking for big risks in drugs whose development hasn’t even begun. The outcome is still always the same = this is a big scam, and even if it isn’t, it’s still a crappy investment. If it ever happens to make money for its owners, even then it will be “wrongly won”.

Faron is, however, the only one of the two who, according to the court, has intentionally given false information before. Short is the memory of recent Faronists.

There has been no clear attempt to manipulate the share price here. Ordinary discussion about a stock is not share price manipulation, no matter how large the audience. Nor is presenting incorrect information due to error or incompetence. Nor is getting excited about a stock or hating a stock and constantly being bearish. Faron also has the right to make mistakes and err in its announcements and slides, as long as false information is not given knowingly and intentionally and is corrected at an appropriate pace. Illegality requires quite aggressive systematic action to sway the share price and gain financial benefit from it, so honest debaters have no need to fear court. So let the discussion continue wild and free, within the forum rules.

Faron Pharmaceuticals

This status offers Faron certain benefits for the development and commercialization of bexmarilimab.

Translation: Original published in Finnish on 3/4/2025 at 7:45 am EET.
Faron&#xa0;<a href="https://www.inderes.se/releases/inside-information-fda-grants-orphan-drug-designation-for-bexmarilimab-in-mds">announced</a> on Monday that it has received Orphan Drug Designation from the US Food and Drug Administration (the FDA) for its investigational drug bexmarilimab for myelodysplastic syndromes (MDS). This status offers Faron certain benefits for the development and commercialization of bexmarilimab. The positive news does not have a significant impact on the success of the drug development and therefore on our forecasts.
<h2>Status offers benefits for orphan drug development</h2>
Faron already has similar status in Europe for MDS and in the US for acute myeloid leukemia (AML). In addition, Faron has received Fast Track designation from the FDA. Orphan Drug Designation qualifies Faron for, among other things, tax credits for clinical testing, exemptions from FDA fees and seven-year marketing exclusivity upon approval (<a href="https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products">reference</a>). The status is intended to support the development of drugs for rare diseases. We have discussed the regulation of drug development in more detail <a href="https://www.inderes.fi/en/analyst-comments/regulation-of-drug-development%23">here</a>.

	2024	25e	26e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-18.7	-18.9	-30.5
EBIT-% (adj.)	-466,750.0 %	-472,000.0 %	-762,390.0 %
EPS (adj.)	-0.25	-0.18	-0.29
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Orphan drug status for Faron in the US

Status offers benefits for orphan drug development

Key Estimate Figures28/02

Forum discussions